EPISODE · Oct 31, 2019 · 35 MIN
Immune Checkpoint Inhibitors In Renal Cell Carcinoma
from AUAUniversity · host American Urological Association
Co-Host: William Huang, MD At the conclusion of these activities, participants will be able to: 1. Discuss the current immunotherapy options available for the treatment of RCC. 2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC. 3. Identify and manage the adverse events related to these agents. CME Available: auau.auanet.org/node/26095 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
What this episode covers
Co-Host: William Huang, MD At the conclusion of these activities, participants will be able to: 1. Discuss the current immunotherapy options available for the treatment of RCC. 2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC. 3. Identify and manage the adverse events related to these agents. CME Available: auau.auanet.org/node/26095 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
NOW PLAYING
Immune Checkpoint Inhibitors In Renal Cell Carcinoma
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.